Recombinant Human IL-32 Protein，His

Interleukin-32 (IL-32) is a pro-inflammatory cytokine that plays a crucial role in the immune response and has been linked to various autoimmune and inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and certain cancers. Discovered in 2005, IL-32 is secreted by various immune cells, such as T cells, natural killer cells, and monocytes, and it influences the production of other cytokines, promoting inflammation. Due to its significant involvement in inflammatory processes, IL-32 has become a target for therapeutic research aimed at modulating immune responses. The study of recombinant IL-32 protein is critical for understanding its biological functions, elucidating its signaling pathways, and developing potential treatments that could mitigate chronic inflammatory conditions. Recombinant production allows for the generation of pure IL-32 for in vitro and in vivo applications, facilitating the exploration of its effects on immune cells and its potential as a biomarker for disease progression. As research progresses, IL-32's role in various pathologies may pave the way for novel therapeutic strategies, indicating its potential as a biomarker and a therapeutic target in diseases characterized by dysregulated immune responses. Overall, the ongoing investigation of IL-32 and its recombinant protein form is essential for advancing our knowledge of cytokine biology and for the development of innovative approaches to manage inflammatory diseases.